ANS Stimulates Wall Street With New Rechargeable IPG, Parkinson’s Trial
This article was originally published in The Gray Sheet
Executive Summary
Advanced Neuromodulation Systems expects the full roll-out of its Eon rechargeable implantable pulse generator in the second half of the year to help propel a continued rebound of the firm's stock
You may also be interested in...
New Products In Brief
St. Jude EonC approval: St. Paul, Minn., firm announces FDA and EU approval of EonC, "the first extended-life primary cell (non-rechargeable) neurostimulator for chronic pain." Device features NeuroDynamix technology to deliver stimulation more efficiently, advanced programming capability to let patients adjust therapy strength in eight pain areas and constant current circuitry that automatically adjusts power output for consistent therapy over time, the company says. St. Jude gained the original Eon, approved in 2005, in its acquisition of Advanced Neuromodulation Systems later that year (1"The Gray Sheet" May 9, 2005, p. 16)
New Products In Brief
St. Jude EonC approval: St. Paul, Minn., firm announces FDA and EU approval of EonC, "the first extended-life primary cell (non-rechargeable) neurostimulator for chronic pain." Device features NeuroDynamix technology to deliver stimulation more efficiently, advanced programming capability to let patients adjust therapy strength in eight pain areas and constant current circuitry that automatically adjusts power output for consistent therapy over time, the company says. St. Jude gained the original Eon, approved in 2005, in its acquisition of Advanced Neuromodulation Systems later that year (1"The Gray Sheet" May 9, 2005, p. 16)
St. Jude Offers $1.3 Bil. For ANS, Citing Low-Voltage Technology Synergy
St. Jude Medical cites technological synergies and near-term revenue growth as justification for its offer to acquire Advanced Neuromodulation Systems for $1.3 bil